Daphne Zohar, PureTech Health CEO
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
The company that spun out Karuna is cashing in on a $500 million deal with Royalty Pharma, just days after the biotech rolled out positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
